Xigduo® (Dapagliflozin + Metformin)

Xigduo® (Dapagliflozin + Metformin) Dapagliflozin 10 mg + Metformin HCl 500 mg and Dapagliflozin 10 mg + Metformin HCl 1000 mg and Dapagliflozin 5 mg + Metformin HCl 1000 mg tablets by AstraZeneca. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.

Additional information

Composition

Dapagliflozin 10 mg + Metformin HCl 500 mg / Dapagliflozin 10 mg + Metformin HCl 1000 mg / Dapagliflozin 5 mg + Metformin HCl 1000 mg

Manufacturer

AstraZeneca

Country

India

Pack size
Storage

Store as per the carton; the US reference label describes 20°C to 25°C.

Prescription medicine

Supplied only against a valid prescription from a registered medical practitioner.

100% genuine

Sourced from authorised channels

Cold-chain delivery

Temperature-controlled packing

Pan-India delivery

Hospitals, clinics, pharmacies

Licensed distributor

Delhi drug licence holder

Product information

Xigduo® (Dapagliflozin + Metformin) Dapagliflozin 10 mg + Metformin HCl 500 mg and Dapagliflozin 10 mg + Metformin HCl 1000 mg and Dapagliflozin 5 mg + Metformin HCl 1000 mg Tablets — SGLT2 Inhibitor and Biguanide Combination Tablets (IR and XR): A Sourcing Guide for Hospitals and Pharmacies

Xigduo® is a brand of dapagliflozin and metformin hydrochloride combination tablets from AstraZeneca, supplied in our range as Xigduo XR extended-release tablets (10 mg/500 mg and 10 mg/1000 mg) and Xigduo immediate-release tablets (5 mg/1000 mg), as shown on the cartons. According to the current US prescribing information for Xigduo XR, the combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, and dapagliflozin is also indicated for risk reduction in chronic kidney disease, heart failure and cardiovascular disease. Indications in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe dapagliflozin + metformin, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.

As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Xigduo® (dapagliflozin + metformin) Dapagliflozin 10 mg + Metformin HCl 500 mg and Dapagliflozin 10 mg + Metformin HCl 1000 mg and Dapagliflozin 5 mg + Metformin HCl 1000 mg tablets to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the diabetes medicines category. Supply is in bulk/wholesale quantities only.


What is Xigduo (Dapagliflozin + Metformin)?

Xigduo contains dapagliflozin and metformin hydrochloride in the strengths and forms listed below.

How it works, according to the label: The reference label describes dapagliflozin as a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin as a biguanide that reduces hepatic glucose production and intestinal glucose absorption and improves insulin sensitivity.


Indications as Listed in the Reference Label

The current US prescribing information for XIGDUO® XR (dapagliflozin and metformin HCl extended-release) tablets (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Xigduo pack insert.

  • Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
  • Dapagliflozin as a component: reduction of the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and heart-failure hospitalisation in specified patients
  • Further cardiovascular and heart-failure indications for the dapagliflozin component, as specified in the label

Clinical Studies and Evidence

The reference label summarises its Clinical Studies by indication. The add-on of dapagliflozin in type 2 diabetes with inadequate glycaemic control on metformin was published by Bailey et al. in The Lancet in 2010, and the DECLARE-TIMI 58 cardiovascular outcomes study of dapagliflozin was published by Wiviott et al. in the New England Journal of Medicine in 2019. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.


Available Strengths and Packs

Strength Dosage form Pack size (as shown on the carton)
Dapagliflozin 10 mg + Metformin HCl 500 mg Extended-release tablets (Xigduo XR) 4 x 7 tablets (28 tablets, as shown on the carton)
Dapagliflozin 10 mg + Metformin HCl 1000 mg Extended-release tablets (Xigduo XR) 28 tablets (as listed)
Dapagliflozin 5 mg + Metformin HCl 1000 mg Immediate-release tablets (Xigduo IR) 14 tablets (as shown on the carton)

Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.


Key Benefits for Procurement

  • Genuine, sealed original-pack stock sourced through authorised channels
  • Multiple strengths of one brand available from a single source
  • Batch and expiry details provided on request
  • Careful handling and storage of stock before dispatch
  • Documentation support for hospital purchase departments

Who Is This Page For?

This page is written for hospital pharmacists, endocrinology and diabetology department buyers and pharmacies that source antidiabetic products. The product is prescribed and supervised by a physician, as described in the prescribing information.


Possible Side Effects Reported in the Label

The reference label carries a boxed warning for lactic acidosis. Its warnings and adverse reactions include ketoacidosis, volume depletion, genitourinary infections (including genital mycotic infections and Fournier’s gangrene) and hypoglycaemia with insulin or secretagogues. This list is not complete; the full prescribing information governs.


Precautions

  • The reference label carries a boxed warning on metformin-associated lactic acidosis, which can result in death.
  • The label describes ketoacidosis, including in patients with type 1 diabetes, and volume depletion as warnings.
  • The label describes contraindications including severe renal impairment and metabolic acidosis.
  • Any decision on use and dosing is made by the treating physician in line with the approved prescribing information.

All use should follow the approved prescribing information and the instructions of the treating physician.


Storage and Handling

Please follow the storage instructions printed on the Xigduo carton and strip. For reference, the US Xigduo XR label describes storage at 20°C to 25°C. Keep out of reach of children.


Manufacturer Information

Xigduo is marketed by AstraZeneca. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Xigduo through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.


Related Medicines


Frequently Asked Questions

Is Xigduo available in India?
A.K. Pharma supplies Xigduo (dapagliflozin + metformin) Dapagliflozin 10 mg + Metformin HCl 500 mg and Dapagliflozin 10 mg + Metformin HCl 1000 mg and Dapagliflozin 5 mg + Metformin HCl 1000 mg tablets to hospitals and pharmacies in India. Contact us for current availability.

What does Xigduo contain?
Dapagliflozin (an SGLT2 inhibitor) with metformin hydrochloride, as extended-release (XR) and immediate-release (IR) tablets.

Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.

How should Xigduo be stored?
Follow the carton and strip; the US reference label describes 20°C to 25°C.

Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.

How do I request a quote?
Call or WhatsApp us, or use the contact details below.


Why Order from A.K. Pharma

  • Licensed pharmaceutical distributor in Delhi with 25+ years in specialty medicines
  • Genuine, original-pack stock
  • Bulk/wholesale supply to hospitals and pharmacies
  • Batch and expiry details on request
  • Dedicated team for hospital procurement queries

Sources and Further Reading


Contact A.K. Pharma for Xigduo Supply

📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in


Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.

Hi! 👋 Looking for a medicine? I can help you find it.

Quote Request Form


Quote Request Form